Table 2.
In the mRNA expression studies, the table shows participant demographics, measurements of bile acid parameters and # of biopsies at 3 locations in 44 patients with IBS-D and 30 healthy controls
| Healthy (N=30) | IBS-D without ABAM (N=34) | BAD (N=10) | |
|---|---|---|---|
| Female: male | 14:16 | 24:10 | 7:3 |
| Age, years (SD) | 45.6 (13.3) | 38.6 (12.9) | 44.7 (11.8) |
| Serum 7αC4 mean (SD) Median (10th–90th percentile) |
19.1 (29.8) 13.9 (4.1–25.5) |
19.2 (13.4) 14.6 (5.6–37.8) |
84.9 (33.2)* 76.4 (55.3–135.5) |
| Serum FGF-19 mean (SD) Median (10th–90th percentile) |
125.1 (142.9) 74.6 (29.5–210.9) |
103.4 (77.0) 80.2 (29.3–215.9) |
67.3 (46.1) 52.6 (21.9–137.3) |
| % faecal CA+CDCA mean (SD) Median (10th–90th percentile) |
NA | 4.2 (2.3) 1.0 (0.34–10.98) |
23.4 (27.0)* 23.7 (0.08–64.52) |
| TI biopsies (# of participants) | 21 | 27 | 7 |
| RC biopsies (# of participants) | 21 | 34 | 10 |
| LC biopsies (# of participants) | 30 | 34 | 10 |
*
P<0.05 versus IBS-D without ABAM.
ABAM, abnormal bile acid metabolism; BAD, bile acid diarrhoea; CA, cholic acid; CDCA, chenodeoxycholic acid; FGF-19, fibroblast growth factor 19 ; IBS-D, irritable bowel syndrome with diarrhoea; LC, left colon; RC, right colon; TI, terminal ileum; 7αC4, 7α-hydroxy-4-cholesten-3-one.